Translating KDIGO Updates and Clinical Evidence Into Managed Care Decision-Making in IgA Nephropathy

Program Description

Immunoglobulin A nephropathy (IgAN) is the most common primary glomerulonephritis worldwide and is a leading cause of kidney failure, with 25% to 30% of patients progressing to end-stage kidney disease. Early detection and appropriate management of IgAN are critical to slowing disease progression and improving long-term patient outcomes. Until recently, therapeutic options for IgAN were largely limited to supportive care and management of secondary symptoms, including renin-angiotensin system (RAS) blockade for blood pressure control and proteinuria reduction. A growing understanding of IgAN pathophysiology, including the multi-hit hypothesis, the role of the gut microbiome and a proliferation-inducing ligand, and complement pathway involvement, has driven the development of multiple FDA-approved therapies and expanded the pipeline of emerging agents.

As the IgAN treatment landscape continues to advance, managed care professionals and pharmacists are uniquely positioned to drive meaningful improvements in patient access and outcomes. This webinar is designed to equip managed care professionals and pharmacists with the clinical and economic knowledge needed to navigate the expanding landscape of therapies in IgAN. In addition to pathophysiology, the discussion will examine risk stratification challenges and updated guideline recommendations, including more stringent proteinuria goals and optimized strategies for preserving kidney function. The program will also address the practical realities facing managed care teams, such as treatment cost considerations, access barriers including prior authorization and step therapy requirements, and formulary management strategies for rare disease therapies.

Target audience: Managed care pharmacists
Type of activity: Application
Release date: August 13, 2026
Expiration date: August 13, 2027
Learner level: Intermediate, Foundational
Time to complete activity: 1.0 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Assess the pathophysiologic mechanisms, clinical course, and patient-level burden associated with immunoglobulin A nephropathy (IgAN)
• Apply evidence-based treatment goals and recommendations outlined in the KDIGO guidelines, with particular emphasis on the clinical relevance of proteinuria reduction
• Analyze emerging pharmacologic therapies for IgA nephropathy by evaluating clinical trial evidence, mechanisms of action, and relevant molecular targets
• Examine coordinated care approaches and practical management strategies to support early detection, timely treatment initiation, and improved long-term kidney outcomes

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-26-265-H01-P. The activity is available for CE credit through August 13, 2027.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Faculty

Ami Gopalan, PharmD, MBA, FAMCP, has the following relevant financial relationships with ineligible companies to disclose:

Other Support: Otsuka

Employee: Precision AQ

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Jason Christidhis, PharmD, RUCIF; Kylie Ferrentino; and Brianna Winters have no relevant financial relationships with ineligible companies to disclose.

Any relevant financial relationships listed for these individuals have been mitigated.

At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.

Educational Disclaimer

Continuing professional education activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved by the labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
ceinfo@pharmacytimes.com
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms